OncoMatch/Clinical Trials/NCT04278287
Chemoradiotherapy in Unresectable Esophageal Cancer
Is NCT04278287 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Albumin-Bound Paclitaxel and Cisplatin for esophageal cancer.
Treatment: Albumin-Bound Paclitaxel · Cisplatin — This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Esophageal Carcinoma
Tumor Agnostic
Disease stage
Required: Stage T3N1M0-1B, T4N0-1M0-1B
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
hemoglobin >= 100g/l; leukocytes >= 4,000 g/l; neutrophil >= 2,000 g/l; platelets >= 100,000/mm3
Kidney function
creatinine <= 1.5x uln or ccr >= 60 ml/min
Liver function
ast/alt <= 2.5x uln; total bilirubin <= 1.5x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04278287 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage T3N1M0-1B or T4N0-1M0-1B is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages